Evidence map›Paper›PMID 39966991›Full record

ArticleJournal of hematology & oncology2025

IL-15: from discovery to FDA approval.

Zihai Li, John Wrangle, Kai He, Jonathan Sprent, Mark P Rubinstein

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hematology & oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Natural and Engineered Cytokines as Cancer Therapeutics.Annual review of cancer biology · 2026
    Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zihai LiPelotonia Institute for Immuno-Oncology, The Ohio State University, Columbus, OH, 43210, USA.
John WrangleDivision of Hematology and Oncology, Department of Medicine, Medical University of South Carolina, Charleston, SC, 29425, USA.
Kai HePelotonia Institute for Immuno-Oncology, The Ohio State University, Columbus, OH, 43210, USA.
Jonathan SprentImmunology Division, Garvan Institute of Medical Research, Darlinghurst, 2010, Australia.
Mark P RubinsteinPelotonia Institute for Immuno-Oncology, The Ohio State University, Columbus, OH, 43210, USA. mark.rubinstein@osumc.edu.

Funding

Lymphocyte and inflammatory cytokine markers of response in the first-in-human combination of anti-PD-1 mAb and IL-15/IL-15Ra complexes and investigation of mediators of anti-tumor immune responsesR01CA222817 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI RUBINSTEIN, MARK P, WRANGLE, JOHN M. · 2019 to 2023
$2.0M
National Institutes for Health R01CA222817NCI NIH HHS R01 CA222817
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID39966991
PMCPMC11837486

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.